|Bid||11.93 x 800|
|Ask||11.96 x 2900|
|Day's Range||11.70 - 12.09|
|52 Week Range||10.00 - 83.10|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.11|
The WeTrader Paper Trading Competition , a 5-week paper trading contest hosted by the zero-commission trading platform Webull, has officially ended. Here’s a look at how the 83 contestants—the top 10 portfolios ...
AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.
(Bloomberg) -- Short-seller Joseph Lawler’s bearish call on AnaptysBio Inc. scored a huge pay-day after the company’s experimental drug, etokimab, failed to meet its goals in an eczema study. The stock tumbled as much as 72% to a record low.Lawler, little known on Wall Street, is the founder of JFL Capital Management and oversees $250 million in Lakeway, Texas. When he pitched AnaptysBio as a short at the Robin Hood conference in New York last year, the shares were trading around $71. Now, the stock is around $11.“There were warning signs everywhere that this program would fail,” Lawler said in an email, adding that he’s still betting against the stock.Lawler’s suspicions dated back to a trial in peanut allergy that the company abandoned last year after it reassessed the market. Back then, he also took issue with the fact that AnaptysBio’s website and regulatory filings erred when they said CEO Hamza Suria had a Bachelor of Science degree from Kalamazoo College. In fact, it was a Bachelor of Arts, and the error got fixed on the company’s website after Bloomberg News asked about it.The etokimab “bombshell” has removed a potential competitor for Dermira Inc., which is working on a rival eczema treatment, SVB Leerink analyst Pasha Sarraf wrote in a note. Shares of Dermira rallied as much as 33%.AnaptysBio’s trial failure is also positive for Regeneron Pharmaceuticals Inc., whose Dupixent drug is on track to double sales in 2019 to $1.8 billion as it expands use in eczema, Bloomberg Intelligence analyst Michael Shah noted. Regeneron shares rose as much as 3.7%.AnaptysBio’s short interest hovered around 13% of shares available for trading, down from 17% in August, according to data compiled by S3 Partners. AnaptysBio said it will continue with a separate study of etokimab in chronic rhinosinusitis with nasal polyps, but has postponed its trial in asthma to do more analysis.(Adds chart, more background starting in fourth paragraph.)To contact the reporter on this story: Tatiana Darie in New York at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Lu WangFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Benzinga Pro's Stocks To Watch For Friday Disney (DIS) - Shares traded 6% higher following better-than-expected Q4 earnings but a slight sales miss. Analysts who responded to the earnings report were mostly ...
Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary EndpointReported Positive Topline Data from Interim.
AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. The Company will be receiving additional data and plans to provide a detailed update in the first quarter of 2020.
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […]
Investing in stocks comes with the risk that the share price will fall. And unfortunately for AnaptysBio, Inc...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE/Nasdaq-listed biotech stocks hit 52-week highs on Oct. 1. Down In The Dumps (Biotech stocks hitting 52-week ...
AnaptysBio stock toppled Tuesday after the biotech company's psoriasis treatment failed to enthuse investors. The company tested just two patients vs. analyst expectations for 10 patients.
AnaptysBio Inc (NASDAQ: ANAB ) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-severe generalized ...
AnaptysBio shares fell to their lowest level in two years after the biotech company released Phase II results that analysts questioned because they included only two participants. SunTrust was "admittedly underwhelmed by the fact that interim data only included 2 subjects while [the] full study is expect[ed] to enroll 10 subjects," according to a Sept. 30 note from analyst Joon Lee, who has a buy recommendation and $93 target on the stock.
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy studyBoth patients achieved the primary endpoint of disease score improvement.
SAN DIEGO, Sept. 27, 2019 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet.
Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019Etokimab Phase 2b Eosinophilic Asthma Trial Initiation Anticipated in 4Q19IND.
SAN DIEGO, Aug. 06, 2019 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet.
AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.